Phase II Human Trial of New Psoriasis Drug Clears Skin in More Than 80% of Patients

by Dr. Trupti Shirole on  July 9, 2015 at 11:52 PM Drug News   - G J E 4
Psoriasis is a chronic skin condition that causes itchy, dry and red skin. It affects nearly 3% of the world's population, and also increases a patient's risk for depression, heart disease and diabetes, among other conditions. People suffering from psoriasis may soon benefit from a drug that offers greater efficacy than the current standard of care, revealed phase II human trial. Nine-month treatment with the new drug was found to clear skin in more than 80% of psoriasis-affected patients.
Phase II Human Trial of New Psoriasis Drug Clears Skin in More Than 80% of Patients
Phase II Human Trial of New Psoriasis Drug Clears Skin in More Than 80% of Patients

First author Kenneth Gordon, professor of dermatology at Northwestern University in the US, said, "The possibility of getting almost all patients nearly clear and able to live their lives without the burden of this disease impacting them every day is getting close to reality. For patients, the concept that psoriasis is 'just something you live with' is no longer appropriate."

Researchers compared the new drug guselkumab to adalimumab, the most common medication currently used to treat psoriasis. In the trial, 293 adult patients with moderate-to-severe psoriasis (defined as covering 10% or more of the body) were randomly assigned to receive varying doses of one of the two drugs or a placebo over 52 weeks. At weeks 16 and 40, efficacy of both the drugs was measured on a scale of zero to five.

A significantly higher number of patients in the guselkumab group had a score of zero (cleared psoriasis) or one (minimal psoriasis) in both the short and long term periods compared to the adalimumab and placebo groups. At week 40, for example, 81% of patients taking a 200-mg dose of guselkumab had a score of zero or one, compared to 49% of patients taking adalimumab. The study said, "The drug works by blocking a protein specifically implicated in psoriasis, called interluekin 23; older drugs affect the immune process more generally."

An ongoing phase III trial is continuing to test the safety and efficacy of guselkumab as a potential psoriasis treatment.

The study is published in the New England Journal of Medicine.

Source: IANS

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like